CA2520406A1 - Cxcr4 antagonists and methods of their use - Google Patents

Cxcr4 antagonists and methods of their use Download PDF

Info

Publication number
CA2520406A1
CA2520406A1 CA002520406A CA2520406A CA2520406A1 CA 2520406 A1 CA2520406 A1 CA 2520406A1 CA 002520406 A CA002520406 A CA 002520406A CA 2520406 A CA2520406 A CA 2520406A CA 2520406 A1 CA2520406 A1 CA 2520406A1
Authority
CA
Canada
Prior art keywords
cancer
cxcr4
cell
antagonist
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002520406A
Other languages
English (en)
French (fr)
Inventor
Hyunsuk Shim
Zhongxing Liang
Jay Umbreit
Russell Taichman
Mark Goodmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
University of Michigan System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2520406A1 publication Critical patent/CA2520406A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002520406A 2003-03-27 2004-03-26 Cxcr4 antagonists and methods of their use Abandoned CA2520406A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45821703P 2003-03-27 2003-03-27
US60/458,217 2003-03-27
PCT/US2004/009570 WO2004087068A2 (en) 2003-03-27 2004-03-26 Cxcr4 antagonists and methods of their use

Publications (1)

Publication Number Publication Date
CA2520406A1 true CA2520406A1 (en) 2004-10-14

Family

ID=33131767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002520406A Abandoned CA2520406A1 (en) 2003-03-27 2004-03-26 Cxcr4 antagonists and methods of their use

Country Status (5)

Country Link
US (1) US20070258893A1 (https=)
EP (1) EP1608318A4 (https=)
JP (1) JP2006524242A (https=)
CA (1) CA2520406A1 (https=)
WO (1) WO2004087068A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US8858914B2 (en) 2002-02-07 2014-10-14 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8865128B2 (en) 2002-02-07 2014-10-21 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8916167B2 (en) 2001-05-02 2014-12-23 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
US9180215B2 (en) 2007-02-07 2015-11-10 Purdue Research Foundation Positron emission tomography imaging method
US9279813B2 (en) 2006-11-03 2016-03-08 Purdue Research Foundation Ex vivo flow cytometry method and device
US9731035B2 (en) 2005-07-05 2017-08-15 Purdue Research Foundation Method of imaging osteoarthritis using a folate conjugate

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004020462A1 (ja) 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
AU2006203826A1 (en) 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
WO2006091112A1 (en) * 2005-02-22 2006-08-31 Genesis Reasearch And Development Corporation Limited Compositions for the delivery of rna interference molecules and methods for their use
US8569280B2 (en) 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
DE102005023170A1 (de) * 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
US9034814B2 (en) 2005-05-25 2015-05-19 Hadasit Medical Research Services And Development Ltd. CXCR4 antagonists for wound healing and re-epithelialization
CA2619828A1 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
EP2397148A3 (en) * 2006-02-02 2012-04-25 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment
TW200808328A (en) * 2006-06-02 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of stromal cell-derived factor 1-related targets for treatment of neovascularization-related conditions
EP2041067A4 (en) 2006-07-11 2009-11-25 Univ Emory CXER4 ANTAGONISTS WITH DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL PROBLEMS
CA2673719C (en) 2006-12-21 2018-07-24 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for bone marrow recovery
EP2197469A2 (en) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection
AU2009228034A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
AU2009311645C1 (en) 2008-11-04 2014-10-02 Acer Therapeutics Inc. CXCR4 receptor compounds
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2011094389A2 (en) * 2010-01-27 2011-08-04 Emory University Cxcr4 antagonists for imaging of cancer and inflammatory disorders
US9155795B2 (en) 2010-02-26 2015-10-13 Anchor Therapeutics, Inc. CXCR4 receptor compounds
US20130310442A1 (en) * 2010-09-09 2013-11-21 Noxxon Pharma Ag SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
EP2663320A1 (en) 2011-01-10 2013-11-20 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2476441A1 (en) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
EP2978439B1 (en) 2013-03-24 2017-08-16 Biokine Therapeutics Ltd. A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
CA2928315C (en) 2013-10-31 2023-03-21 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
CA2937992A1 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
KR101700946B1 (ko) * 2014-11-11 2017-02-02 연세대학교 산학협력단 Ｃｘｃｒ４ 길항제를 포함하는 피부 색소침착의 예방 또는 개선용 조성물
US11311552B2 (en) * 2015-04-02 2022-04-26 Proximagen, Llc Therapies for cancer
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
WO2017011517A1 (en) 2015-07-16 2017-01-19 Emory University Bis-amines, compositions, and uses related to cxcr4 inhibition
US10434195B2 (en) 2015-08-03 2019-10-08 Emory University Methylsulfonamide derivatives and uses related thereto
CN109310733A (zh) 2016-02-23 2019-02-05 百欧林纳克斯有限公司 治疗急性骨髓性白血病的方法
EP3856225A1 (en) 2018-09-25 2021-08-04 BioLineRx Ltd. Methods of selecting treatment for cxcr4-associated cancer
CN110590744B (zh) * 2019-07-03 2021-11-02 河南省人民医院 一种靶向趋化因子受体cxcr4的小分子类pet显像剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009152A1 (en) * 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO2004020462A1 (ja) * 2002-08-27 2004-03-11 Fujii, Nobutaka Ｃｘｃｒ４拮抗薬およびその用途

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916167B2 (en) 2001-05-02 2014-12-23 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8858914B2 (en) 2002-02-07 2014-10-14 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8865128B2 (en) 2002-02-07 2014-10-21 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US9731035B2 (en) 2005-07-05 2017-08-15 Purdue Research Foundation Method of imaging osteoarthritis using a folate conjugate
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US9279813B2 (en) 2006-11-03 2016-03-08 Purdue Research Foundation Ex vivo flow cytometry method and device
US9180215B2 (en) 2007-02-07 2015-11-10 Purdue Research Foundation Positron emission tomography imaging method
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections

Also Published As

Publication number Publication date
EP1608318A2 (en) 2005-12-28
US20070258893A1 (en) 2007-11-08
WO2004087068A3 (en) 2006-02-02
WO2004087068A2 (en) 2004-10-14
EP1608318A4 (en) 2009-07-29
JP2006524242A (ja) 2006-10-26

Similar Documents

Publication Publication Date Title
CA2520406A1 (en) Cxcr4 antagonists and methods of their use
KR102473113B1 (ko) 암 치료를 위한 병용 요법
KR20180100599A (ko) 종양 치료용 항-cd20 조합물
JP7678032B2 (ja) がん療法において使用するためのデオキシシチジン誘導体又はデオキシウリジン誘導体
CN107683139A (zh) 用于治疗b细胞恶性肿瘤的赛度替尼
JP2016517401A (ja) 結腸直腸癌を処置する方法
AU2017321322A1 (en) Compositions and methods for treatment of prostate cancer
US8008354B2 (en) Death receptor sensitizing compounds and methods of use therefor
CN115605232A (zh) 用于治疗b-细胞淋巴瘤的联合疗法和生物标志物
TWI753178B (zh) Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
US20080206287A1 (en) Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
US20190133998A1 (en) Treatment of tumors with inhibitors of cxcl12 signaling and subtherapeutic amounts of chemotherapeutic agents
US20090041751A1 (en) Sepsis Prevention Through Adenosine Receptor Modulation
EP4361136A1 (en) Compound for the treatment of glioblastoma
Rossetti Caratterizzazione funzionale e molecolare di inibitori farmacologici ad attività anti-istone-deacetilasica, in modelli in vitro ed in vivo di Rabdomiosarcoma
HK40130419A (en) Deoxy- cytidine derivatives for use in cancer therapies
AU2024351866A1 (en) Novel combination therapy for blood cancer
HK40091434A (en) Deoxy- cytidine derivatives for use in cancer therapies
HK40091434B (en) Deoxy- cytidine derivatives for use in cancer therapies
BR122024025392A2 (pt) Uso de um composto, kit e composição farmacêutica
against CXCR Inhibition of Breast Cancer Metastasis by Selective Synthetic

Legal Events

Date Code Title Description
FZDE Discontinued